MIF

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

Retrieved on: 
Friday, July 22, 2022
IPF, Multiple sclerosis, GLOBE, MPH, Injection, Glioblastoma, U.S. Securities and Exchange Commission, Amyotrophic lateral sclerosis, Trial of the century, Neurodegeneration, Code, Acute respiratory distress syndrome, Intellectual property, Form 8-K, Private Securities Litigation Reform Act, NAFLD, PDE4, Risk, Failure, NASDAQ, DCM, CIPN, MS, ALS, FDA, MD, Security (finance), Tokyo Stock Exchange, Patient, Pharmacokinetics, Annual report, Chemotherapy-induced peripheral neuropathy, Idiopathic pulmonary fibrosis, Non-alcoholic fatty liver disease, Nasdaq, Form 10-K, MIF, Pharmaceutical industry, Doctor of Philosophy

The newly developed MN-166 (ibudilast) formulation will provide an additional option for health care providers to administer MN-166 (ibudilast), in addition to the current oral formulation.

Key Points: 
  • The newly developed MN-166 (ibudilast) formulation will provide an additional option for health care providers to administer MN-166 (ibudilast), in addition to the current oral formulation.
  • With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166.
  • Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development.
  • MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Apaxen appoints Graham K. Dixon as Chairman and prepares for clinical testing of its lead inflammasome inhibitor

Retrieved on: 
Monday, July 18, 2022
Patient, Time, NLRP3, Pulmonary fibrosis, MIF, Macrophage migration inhibitory factor domain, IND, Inflammasome, Board of directors, Biotechnology, Board, Company, Growth, Degenerative disease, Doctor of Philosophy, Therapy, VC, Director, Pharmaceutical industry

The appointment of Dr Graham Dixon as Chairman is an important step in the transformation of Apaxen from a pre-clinical to a clinical stage company.

Key Points: 
  • The appointment of Dr Graham Dixon as Chairman is an important step in the transformation of Apaxen from a pre-clinical to a clinical stage company.
  • He is an experienced non-executive director and board chairman as well as an advisor to several venture capital organisations and their portfolio companies.
  • Graham Dixon, newly appointed Chairman of Apaxen, comments:
    "I am very excited to join the Apaxen team.
  • The Apaxen team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors.

Apaxen appoints Graham K. Dixon as Chairman and prepares for clinical testing of its lead inflammasome inhibitor

Retrieved on: 
Monday, July 18, 2022
Patient, Time, NLRP3, Pulmonary fibrosis, MIF, Macrophage migration inhibitory factor domain, IND, Inflammasome, Board of directors, Biotechnology, Board, Company, Growth, Degenerative disease, Doctor of Philosophy, Therapy, VC, Director, Pharmaceutical industry

The appointment of Dr Graham Dixon as Chairman is an important step in the transformation of Apaxen from a pre-clinical to a clinical stage company.

Key Points: 
  • The appointment of Dr Graham Dixon as Chairman is an important step in the transformation of Apaxen from a pre-clinical to a clinical stage company.
  • He is an experienced non-executive director and board chairman as well as an advisor to several venture capital organisations and their portfolio companies.
  • Graham Dixon, newly appointed Chairman of Apaxen, comments:
    "I am very excited to join the Apaxen team.
  • The Apaxen team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors.

Y Soft Acquires EveryonePrint

Retrieved on: 
Wednesday, July 6, 2022
Y Soft, Digital transformation, Acquisition, CEO, Research, EMEA, MIF, Union, SMB, Software as a service, IDC, Contract, Technology, HCP, Name, CTO, VP, ARC Document Solutions, Y, Education, MFD, Video game console, 3D printing, Cloud, Printing, DALLAS

BRNO, Czech Republic and DALLAS, July 6, 2022 /PRNewswire/ -- Y Soft®, the leading digital transformation office solution provider, today announced a definitive agreement to acquire EveryonePrint A/S, a leading provider of Cloud-based document infrastructure.  With this acquisition, Y Soft strengthens its position as a leading provider offering an integrated print management and document capture platform for Cloud and on-premises deployments.

Key Points: 
  • Y Soft chose to acquire EveryonePrint because of its robust Cloud architecture, long-standing and diverse SaaS, Cloud and channel expertise, and strong focus on end-customer value and simplicity.
  • "We are thrilled to add EveryonePrint's technology to our roadmap, as well as the amazing new talent to the Y Soft family," said Vclav Muchna, Y Soft CEO and co-founder.
  • "I can assure EveryonePrint customers and partners that Y Soft will continue to support EveryonePrint's products on a global basis.
  • Y Soft, YSoft SAFEQ, YSoft SAFEQ Cloud and YSoft OMNI Bridge are trademarks or registered trademarks of Y Soft Corporation a.s. in the European Union and other countries.

Importance of Spatial Distribution Insight from Clinical Biopsies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, June 30, 2022
Review, Innovation, Biomarker, TME, Patient, Tumor microenvironment, Neoplasm, MD–PhD, Industry, MIF, H&E, Spatial distribution, Food, Medical imaging

TORONTO, June 30, 2022 /PRNewswire-PRWeb/ -- Current immuno-oncology research is revealing diagnostic, prognostic and predictive cell states and identities with implications for drug and diagnostic development as well as diagnostic testing. However, it is challenged in that only a minority of patients respond.

Key Points: 
  • In this free webinar, learn how spatial biology can provide insights into the spatial distribution and cellular interactions in clinical tumor biopsies.
  • The need for spatial distribution in clinical biopsies is now more than ever.
  • Join this webinar to learn how spatial biology can provide insights into the spatial distribution and cellular interactions in clinical tumor biopsies.
  • For more information, or to register for this event, visit Importance of Spatial Distribution Insight from Clinical Biopsies.

MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on: 
Thursday, June 30, 2022
FDA, Patient, Code, Amyotrophic lateral sclerosis, MS, Program, Proning, Biomedical Advanced Research and Development Authority, IPF, Nasdaq, MIF, GLOBE, NAFLD, Chlorine, CIPN, Failure, Multiple sclerosis, ALI, United States Department of Health and Human Services, Intellectual property, U.S. Securities and Exchange Commission, ALS, Annual report, PDE4, Redirect, Tokyo Stock Exchange, Development, Glioblastoma, MCM, Chemotherapy-induced peripheral neuropathy, Idiopathic pulmonary fibrosis, Risk, Acute respiratory distress syndrome, Security (finance), Drive, Private Securities Litigation Reform Act, Radiation, Human services, BARDA, NASDAQ, Non-alcoholic fatty liver disease, Form 10-K, DCM, Neurodegeneration, Form 8-K, Pharmaceutical industry, Research

Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Key Points: 
  • Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
  • MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, June 8, 2022
Soft tissue injury, Oxygen, IPF, Death, Coronavirus, Pneumonia, Intellectual property, NIAID, DCM, Acute respiratory distress syndrome, CIPN, Form 10-K, Form 8-K, Annual report, Neurodegeneration, NAFLD, Glioblastoma, Tokyo Stock Exchange, Security (finance), U.S. Securities and Exchange Commission, Inflammation, Amyotrophic lateral sclerosis, Female, Failure, Non-alcoholic fatty liver disease, Vaccine, MIF, FDA, Proning, Patient, Infection, MS, Risk, Chemotherapy-induced peripheral neuropathy, GLOBE, ALS, Code, Private Securities Litigation Reform Act, COVID-19, Atmosphere, NASDAQ, Courage, Male, Nasdaq, MD, Clinical trial, Virus, Multiple sclerosis, Oxygen saturation (medicine), MPH, PDE4, Carbon, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Medical imaging, Doctor of Philosophy

The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure.

Key Points: 
  • The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure.
  • The clinical trial enrolled 36 subjects and randomized 34 subjects including 17 subjects in the MN-166 (ibudilast) group and 17 subjects in the placebo group.
  • Male and female participants (mean age = 60 years) were equally represented in MN-166 (ibudilast) and placebo treatment groups.
  • In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).

Nucleai Announces Partnership with Ultivue to Provide AI-Powered Spatial Biology Analysis to Complex Pathology Images

Retrieved on: 
Thursday, June 2, 2022
Data Management, Biotechnology, Technology, Health, Radiology, Pharmaceutical, Other Technology, Research, Software, Science, Clinical Trials, Biomarker, Precision medicine, Research, Artificial intelligence, VUE, Pathology, Partnership, Algorithm, MIF, Solution, IHC, Industry, Drug development, Spatial analysis, Medical imaging, Sutro Biopharma

The partnership will layer Nucleais cutting-edge AI spatial models on top of Ultivues imaging technology to unlock the complex data hidden within multiplex pathology images, creating insights for translational research teams across Biopharma to expedite drug development.

Key Points: 
  • The partnership will layer Nucleais cutting-edge AI spatial models on top of Ultivues imaging technology to unlock the complex data hidden within multiplex pathology images, creating insights for translational research teams across Biopharma to expedite drug development.
  • This collaborative partnership will allow both Ultivue and Nucleai to provide their customer bases with state-of-the-art multiplex images and insights.
  • Additionally, Ultivue will be able to offer automated biomarker quantification and complex spatial insights alongside their mIF imaging services.
  • Founded in 2018, Nucleai is a precision medicine company that has developed an AI-powered pathology-based biomarker discovery platform to unlock the power of spatial biology from pathology images.

Ultivue Announces AI Partner Ecosystem to Accelerate Analysis of Multiplex Immunofluorescence Image Data in Translational Medicine

Retrieved on: 
Thursday, May 12, 2022
Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Medical Devices, Clinical Trials, Other Technology, Science, Biotechnology, Software, Other Science, Health, Research, MIF, Data analysis, AI, Science, Solution, Workflow, H&E, Research, Industry, Pathology, Precision medicine, Quality control, GCP, Medical imaging, Sutro Biopharma

Ultivue develops unique workflows for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.

Key Points: 
  • Ultivue develops unique workflows for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.
  • Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation.
  • Ultivue is complementing its own Image Data Services with capabilities provided by trusted partners to offer end-to-end support for customers.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.